H.C. Wainwright initiated coverage on Trevi Therapeutics with a new price target
$TRVI
Biotechnology: Pharmaceutical Preparations
Health Care
H.C. Wainwright initiated coverage of Trevi Therapeutics with a rating of Buy and set a new price target of $21.00